ALNY Financial Facts
Net loss per common share - basic and diluted: -0.15General and administrative: 6.27M
See Full Income Statement
Accounts payable: 3.11M
Marketable securities: 138.21M
See Full Balance Sheet
Earnings History for Alnylam Pharmaceuticals, Inc. (ALNY)
|
Expand Research on ALNY
| Next EPS Date | 8/5/13 *Est. | EPS Growth Rate | +40.0% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | +8.1% | Revenue Growth Rate | -9.7% *Last Qtr. |
| Average % Move 1-Wk after EPS | +1.5% |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Estimize EPS/Revs | Gd. | % Since | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 5/6/13 |
Q113 | -$0.15 | -$0.29 | +$0.14 | $18.6M | $15.56M | N/A / N/A | N/A | +27.1% | Details | |
| 2/7/13 |
Q412 | -$1.20 | -$1.48 | +$0.28 | $8.5M | $15.82M | N/A / N/A | N/A | +27% | Details | |
| 11/5/12 |
Q312 | -$0.31 | -$0.30 | -$0.01 | $16.8M | $17M | N/A / N/A | N/A | +81% | Details | |
| 8/6/12 |
Q212 | -$0.25 | -$0.19 | -$0.06 | $20.9M | $20.81M | N/A / N/A | N/A | +63.3% | Details | |
| 5/3/12 | Q112 | -$0.25 | -$0.36 | +$0.11 | $20.6M | $19.57M | N/A / N/A | N/A | +194% | Details | |
| 2/9/12 |
Q411 | -$0.33 | -$0.32 | -$0.01 | $20.5M | $20.9M | N/A / N/A | N/A | +132% | Details | |
| 11/1/11 |
Q311 | -$0.31 | -$0.35 | +$0.04 | $20.8M | $20.51M | N/A / N/A | N/A | +291.3% | Details | |
| 8/1/11 |
Q211 | -$0.33 | -$0.36 | +$0.03 | $20.6M | $19.97M | N/A / N/A | N/A | +220.8% | Details |
